期刊文献+

恩度联合化疗治疗晚期非小细胞肺癌的临床疗效分析 被引量:9

下载PDF
导出
摘要 目的:通过探讨恩度联合化疗治疗晚期非小细胞肺癌的临床疗效,旨在为临床提高治疗有效率延长患者生命提供理论依据。方法:选择晚期非小细胞肺癌患者46例,随机平均分成研究组和对照组两组。对照组给予患者单纯化疗治疗,研究组给与患者恩度联合化疗治疗,对比两组患者近期总有效率、疾病进展时间及不良反应率。结果:研究组患者治疗后近期总有效率为69.56%,疾病进展时间为7.54个月,均显著优于对照组,差异有统计学意义(P<0.05),同时研究组患者不良反应率为21.74%,与对照组差异无统计学意义(P>0.05)。结论:恩度联合化疗治疗晚期非小细胞肺癌可以显著提高近期总有效率、延长疾病发展时间、不良反应小,是一种安全高效的治疗方式。
作者 丁伶俐
机构地区 吉林省柳河医院
出处 《吉林医学》 CAS 2015年第10期2094-2094,共1页 Jilin Medical Journal
  • 相关文献

参考文献3

二级参考文献19

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 2SCHILLER J H, HARRINGTON D, BELANI C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2) :92-98.
  • 3BUTTS C A, BODKIN D, MIDDLEMAN E L, et al. Randomized phase Ⅱ study of gemcitabine plus eisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small cell lung cancer[ J]. J Clin Oncol, 2007, 25 (36) : 5777-5784.
  • 4SANDLER A, GRAY R, PERRY M C, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer [ J ]. N Eng J Med, 2006, 355(24) :2542-2550.
  • 5RECK M, VON PAWEL J, ZATLOUKAL P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil[J]. J Clin O,wol, 2009, 27(8) :1227-1234.
  • 6SANDLER A B, NEMUNAITIS J, DENHAM C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer[ J ]. J Clin Oncol, 2000, 18( 1 ) : 122-130.
  • 7GATZEMEIER U, VON PAWEL J, GOTTFRIED M, et al. Phase Ⅲ comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer[J]. J Clin Oncol, 2000, 18(19) :3390-3399.
  • 8GIACCONE G, SPLINTER T A, DEBRUYNE C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group[J]. J Clin Oneol, 1998, 16(6) :2133-2141.
  • 9GEORGOULIAS V, ARDAVANIS A, AGELIDOU A, et al. Docetaxel versus doeetaxel plus cisplatin as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, muhicenter phase Ⅲ trial [ J ]. J Clin Oncol, 2004, 22 ( 13 ) : 2602-2609.
  • 10FOSSELLA F, PEREIRA J R, VON PAWEL J,et al. Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group[J]. J Clin Oncol, 2003, 21 (16) :3016-3024.

共引文献50

同被引文献54

引证文献9

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部